Eric Secemsky, MD
Interventional Cardiology · Boston, MANPI 1942535489
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.7%), speaking fees and other — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by Boston Scientific at 25.8% of the total. 2025 is the largest year on record at $349,153, 7.7 times the $45,213 reported in 2019. Among interventional cardiology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,045 payments — averaging $1104.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$298K
- Medtronic$223K
- Philips North America LLC$140K
- Bard Peripheral Vascular, Inc.$93K
- Shockwave Medical, Inc$46K
- Abbott$40K
- plus $316K from 42 others
Across 131 payments — averaging $50,541 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$4M
- Boston Scientific$1.4M
- Bard Peripheral Vascular, Inc.$370K
- Medtronic$242K
- Cook Research Incorporated$194K
- C. R. Bard, Inc. & Subsidiaries$120K
- plus $341K from 6 others
Across 1 payment — averaging $3565.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Inquis Medical, Inc.$4K
What the payments were for
- Consulting fees$665,51058%
- Speaking & faculty fees$216,58119%
- Grants$2,2000%
- Travel & lodging$107,1679%
- Food & beverage$29,1683%
- Gifts$1080%
- Other$133,51012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$160,326
- (9520) IGT Devices Undivided$90,989
- IN.PACT Admiral$56,272
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$44,845
- HawkOne$30,526
- FLEX Vessel Prep System$30,490
- SYMPLICITY G3$19,961
- GORE VIABAHN VBX Balloon Expandable Endo$19,799
- VasQ External Support$19,372
- GENERAL VASCULAR INTERVENTION$18,746
- ELIQUIS$16,000
- Peripheral Orbital Atherectomy System$15,863
- Diamondback Peripheral$15,795
- IGT Devices Und$14,055
- BioMimics 3D Vascular Stent System$14,000
- SELUTION SLR PTA$12,219
- Indigo System$12,000
- ELUVIA$11,746
- CLINICAL TRIAL PRODUCT$11,000
- XARELTO$10,526
How this compares
$1,154,244 in reported general payments places this provider in the 95th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 20 | $23,908 |
| EliquisApixaban | 17 | $15,829 |
| Cilostazol | 20 | $957 |
| Atorvastatin Calcium | 20 | $348 |
| Rosuvastatin Calcium | 22 | $333 |
| Metoprolol Succinate | 11 | $176 |
| Carvedilol | 21 | $157 |
| Losartan Potassium | 20 | $141 |
| Amlodipine Besylate | 18 | $127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $7,717 | $23,90820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 128 interventional cardiology providers in Massachusetts.
Other interventional cardiology in Boston
- Darshan DoshiBoston$730K
- Charles GibsonBoston$661K
- Duane PintoBoston$491K
- Robert YehBoston$412K
- Suzanne BaronBoston$274K
- Farouc JafferBoston$213K
- Joseph GarasicBoston$152K
- Pinak ShahBoston$147K
- Douglas DrachmanBoston$132K
- Hector Tamez AguilarBoston$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.